Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra. As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra. Madrigal’s new pipeline addition has already demonstrated positive results in a Phase I trial. Credit: Piotr Swat/Shutterstock.com. Madrigal Pharmaceuticals has gained the global rights to Arrowhead Pharmaceuticals’ small interfering RNA (siRNA) asset for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The licence agreement, which is worth up to $1bn, sees Madrigal assume development, manufacturing, and commercialisation duties for Arrowhead’s ARO-PNPLA3. The deal includes $25m…

Source: Pharmaceutical Technology